** Noxopharm NOX.AX soars 12.9% to A$0.096, snapping three sessions of declines
** Stock set for biggest intraday pct gain since Nov. 15, 2024
** Biotech co says its lupus medication has passed a set of pre-clinical safety tests, a requisite for drug development prior to Phase 1 clinical trial
** Around 326,347 shares traded, 2.3x the 30-day avg
** NOX gains 3.2% YTD
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((Jasmeenaraislam.shaikh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.